Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up by Schepers, Eva et al.
RESEARCH ARTICLE Open Access
Assessment of the association between
increasing membrane pore size and
endotoxin permeability using a novel
experimental dialysis simulation set-up
Eva Schepers1* , Griet Glorieux1, Sunny Eloot1, Michael Hulko2, Adriana Boschetti-de-Fierro2, Werner Beck2,
Bernd Krause2 and Wim Van Biesen1
Abstract
Background: Membranes with increasing pore size are introduced to enhance removal of large uremic toxins with
regular hemodialysis. These membranes might theoretically have higher permeability for bacterial degradation
products. In this paper, permeability for bacterial degradation products of membranes of comparable composition with
different pore size was investigated with a new in vitro set-up that represents clinical flow and pressure conditions.
Methods: Dialysis was simulated with an AK200 machine using a low-flux, high-flux, medium cut-off (MCO) or high
cut-off (HCO) device (n = 6/type). A polyvinylpyrrolidone-solution (PVP) was recirculated at blood side. At dialysate side,
a challenge solution containing a filtrated lysate of two water-borne bacteria (Pseudomonas aeruginosa and
Pelomononas saccharophila) was infused in the dialysate flow (endotoxin ≥ 4EU/ml). Blood and dialysate flow were set
at 400 and 500 ml/min for 60 min. PVP was sampled before (PVPpre) and after (PVPpost) the experiment and dialysate
after 5 and 55 min. Limulus Amebocyte Lysate (LAL) test was performed. Additionally, samples were incubated with a
THP-1 cell line (24 h) and IL-1β levels were measured evaluating biological activity.
Results: The LAL-assay confirmed presence of 9.5 ± 7.4 EU/ml at dialysate side. For none of the devices the LAL activity
in PVPpre vs. PVPpost was significantly different. Although more blood side PVP solutions had a detectable amount of
endotoxin using a highly sensitive LAL assay in the more open vs traditional membranes, the permeability for
endotoxins of the 4 tested dialysis membranes was not significantly different but the number of repeats is small. None
of the PVP solutions induced IL-1β in the THP-1 assay.
Conclusions: A realisitic in vitro dialysis was developed to assess membrane translocation of bacterial products. LAL
activity on the blood side after endotoxin exposure did not change for all membranes. Also, none of the PVPpost
solutions induced IL-1β in the THP-1 bio-assay.
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Background
Novel insights in uremic toxicity over the last decade
have revealed that retention products in the middle
molecular weight range 15–45 kDa might substantially
contribute to the enhanced inflammation and cardio-
vascular mortality observed in patients with end stage
kidney disease (ESKD) [1, 2]. Conventional high-flux
dialyzers do not efficiently remove molecules in this
molecular weight range, such as β2-microglobulin
(β2M), tumor necrosis factor (TNF)-α, interleukins
(ILs), and complement factor D, resulting in their accu-
mulation in patients with ESKD [3]. The theoretical ad-
vantages of high-flux over low-flux membranes are not
completely translated in clinical advantages, as demon-
strated in the HEMO and MPO study [4–7]. Hemodia-
filtration with postdilution does result in enhanced
removal of these middle molecules [8], but also here,
evidence to support their advantages in the clinical set-
ting is conflictive [9–11], and part of the reported dose-
response effect, with the largest effect observed in the
subgroups with the highest substitution rates, might be
due to confounding as patients in these subgroups typ-
ically have the best vascular access. In addition, hemo(-
dia)filtration increases technical complexity and cost of
dialysis, and requires the application of high volumes of
ultrapure dialysate and sterile substitution fluid with
dedicated equipment.
Nowadays, there is a trend to further increase pore
size and permeability of dialysis membranes to enhance
removal of uremic toxins in the larger molecular weight
range even when used in hemodialysis mode. The high
cut-off (HCO) dialyzers allow elimination of molecules
up to 45 kDa [12] and remove specific middle mole-
cules more effectively than standard high flux mem-
branes [13, 14]. The use of these membranes decreases
inflammation and in vitro calcification, but also results
in albumin loss [15, 16]. More recently, membranes
with a steeper cut-off at a lower molecular weight level
than the HCO membranes, the so-called medium cut-
off (MCO) membranes, have been introduced [17].
These membranes can even remove large toxins such
as kappa and lambda free light chains [18], two
compounds associated with inflammatory markers and
mortality in CKD [19–22]. In a recent randomized
cross-over trial, use of MCO dialyzers during a 12 week
study period was associated with a more expressed
reduction of inflammation than the use of conventional
high-flux dialyzers. However, in this study, ultrapure
dialysate was used [23].
The question arises whether these membranes with in-
creasing pore size also have higher permeability for en-
dotoxins and other bacterial degradation products
potentially present in dialysis fluids. This permeability
issue is relevant since chronic exposure of hemodialysis
(HD) patients to low levels of cytokine-inducing micro-
bial components can potentially contribute to the micro-
inflammatory status of these patients, thus neutralizing
an eventual positive effect induced by their capacity of
enhanced removal of pro-inflammatory uremic toxins
[24, 25]. Therefore, the request for ultrapure dialysate
might become a more important concern as membrane
pore size becomes larger, even when applied in
hemodialysis mode. The International Organization for
Standardization (ISO) published the ISO11663:2014
which states that the dialysate should contain less than
100 colony forming units (CFU)/ml for bacteria and less
than 0.5 endotoxin units (EU)/ml for endotoxin [26].
Standard methods to determine biological contamin-
ation of the dialysate are bacterial culture and the Lim-
ulus Amebocyte Lysate (LAL) assay. To test true
biological response with more clinical relevance, bio-
assays, such as the one using the THP-1 cell line, can be
applied [27].
Assessment of endotoxin transfer over membranes has
until now only been performed in closed in vitro dialysis
circuits. [28–32]. In vitro investigations using miniatur-
ized dialyzer modules of membranes with increasing
pore size have indicated that endotoxin permeability
with lipopolysaccharide (LPS) isolated from E.coli
O55:B5 as a challenge and the LAL assay as read-out
does not increase with increasing pore size [33]. How-
ever, none of these models used clinically relevant blood
and/or dialysate flows, contamination exposure was ra-
ther high in most studies, and the biological response
was assessed in biological assays using whole blood or
isolated peripheral blood mononuclear cells which coin-
cides with a need for healthy donors, large variability
and lower sensitivity compared to the THP-1 assay.
In the present study a more advanced and realistic
dialysis set-up using full sized dialysers was developed
that simulates the clinical situation in terms of flow
rates and viscosity of the medium perfused in the
blood compartment, and using full sized dialyzers.
This set-up was used to assess commercial dialyzers
of comparable composition but with different pore
size for their permeability for bacterial degradation
products by means of a biological assay sensitive to
several bacterial components as read-out in addition
to the LAL assay.
Methods
Dialysis membranes
The dialysis membranes to be evaluated for their endotoxin
permeability were provided by the manufacturer (Polyflux®
17 L, Revaclear 400, Theranova 400 and Theralite™ 2100,
Baxter, Hechingen, Germany) and were composed of com-
parable polymers, but with a different pore size. Their main
characteristics are summarized in Table 1.
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Dialysate and blood substitution fluids
Ultrapure dialysis fluid was prepared on-line with an
AK200 dialysis machine (Gambro, Lund, Sweden) using
a smartbag® (Fresenius Medical Care, Willebroek,
Belgium) acid concentrate and a BiCart™ cartridge
(Gambro) resulting in a dialysate containing 3 mM K+,
140 mM Na+, 1.25 mM Ca2+, 0.50 mM Mg2+ and
34 mM bicarbonate.
A 1.25% polyvinylpyrrolidone (PVP) (Luvitec® K85
powder, BASF, New Jersey, USA) solution was prepared
in sterile PBS 10×, pH 7.2 (Gibco, Life technologies,
Paisley, UK) and diluted 1:10 in sterile water (Braun,
Melsungen, Germany) to achieve a solution with a kine-
matic viscosity of 4 mm2/s, to mimic the viscosity of
whole blood [34]. Viscosity was verified with an Ubbe-
lohde Capillary Viscometer avs310 (SCHOTT Instru-
ments, Weilheim, Germany). For each experiment, 3 L
of this solution was prepared and recirculated through
the blood compartment of the dialyzer.
Compatibility of PVP dissolved in PBS (PVPPBS) with
both the LAL-assay and THP-1 assay was evaluated per
se and in combination with LPS in comparison to PBS.
No interference of the PVP dissolved in PBS could be
observed in both assays.
Challenge solution
The ISO11663:2014 standard for LPS allows less than
0.5 EU/mL in dialysis fluid [26]. In the in vitro experi-
mental set-up, the duration of a dialysis session was set
to 1 h. Corresponding to the total exposure during a
regular dialysis session of 4 h a minimum endotoxin
load of 2 EU/ml should be aimed for. However, to create
a worst case scenario, this load was increased, aiming at
a dialysis fluid containing at least 4 EU/ml. To obtain
this, a concentrated solution (200 EU/ml) of two clinic-
ally relevant water-borne bacterial species, Pseudomonas
aeruginosa and Pelomonas saccharophila (BCCM/LMG,
Gent, Belgium), was prepared [35, 36]. Both strains were
cultured separately to a final concentration of 5.0 ×
1010 CFU/ml for P. aeruginosa and 3.3 × 1010 CFU/ml
for P. saccharophila, and harvested. The bacteria were
treated with heat (20 min, 95 °C) followed by ultrasound
(1 min, 10 rpm) to induce bacterial disintegration. The
obtained lysates were combined as equal endotoxin units
(65,000 EU of P. aeruginosa plus 65,000 EU of P. sac-
charophila) and diluted up to 50 ml with dialysis fluid to
a total concentration of 2600 EU/ml. This solution was
filtered [28–30, 32], with a Millex 33 mm Sterile Filter
Unit with 0.45 μm pore size Durapore® membrane
(Merck KGaA, Darmstadt, Germany) (1 filter per 10 ml)
and further diluted up to 200 EU/ml with dialysis fluid.
The solution was transferred to a sterile bag (Beldico,
Marche-en-Famenne, Belgium) to be infused continu-
ously into the dialysate circuit, aiming at a final concen-
tration in the dialysate of 4 EU/ml.
Dialysis machine set-up
The AK200 dialysis machine was set in double needle
treatment and the tubings for hemodialysis (Gambro)
and the dialyzers were connected. The different mem-
branes were tested in random order as determined by an
Excel based random generator; for each membrane type
6 different dialyzers were tested. The consecutive experi-
mental steps are summarized in Table 2.
First the blood circuit of the dialyzer was primed with
0.9% NaCl (Clear-flex, Baxter, Lessen, Belgium), followed
by further priming of the dialysate circuit with ultrapure
dialysis fluid. After discarding the priming solution, 1 L
of human plasma (Octaplas, Octapharma, Langenfeld,
Germany) was recirculated through the blood circuit
side of the dialyzer with a bloodflow rate (QB) of
200 ml/min at 37 °C for 40 min with continuous mixing
in the reservoir on a magnetic stirrer, in order to coat
the membrane with plasma proteins [31, 37, 38]. During
this procedure, the dialysate circuit was sealed off (di-
alysate flow rate (QD) = 0 ml/min) and no ultrafiltration
was allowed (ultrafiltration flow rate (QF) = 0 ml/min).
Afterwards the blood circuit was rinsed with PBS for
18 min at a QB of 200 ml/min in isolated filtration mode
(ultrafiltration (UF) volume = 1.8 L/h). Then the PBS in
the circuit was exchanged with the PVP solution.
During the actual experiment 3 L of the PVP solution at
37 °C was recirculated during 60 min at a QB of 400 ml/
min while the PVP pool was continuously mixed. The di-
alysate flow was set at 500 ml/min and the challenge solu-
tion was continuously infused from the sterile bag into the
dialysate line before inlet of the dialyzer at a rate of 10 ml/
min with a droplet pump (Cardinal Health, Brussels,
Table 1 Characteristics of dialyzers
Type Sterilisation Membrane Polymer Effective Surface area (m2) UF-coefficient (mL/H/mmHg) Pore radiusa (nm)
Polyflux 17 L Low flux Steam PAES/PVP/PA 1.7 12.5 3.1 ± 0.2
Revaclear 400 High flux Steam PAES/PVP 1.8 54.0 3.9 ± 0.1
Theranova 400 Medium cut off Steam PAES/PVP 1.7 48.0 5.0 ± 0.1
Theralite 2100 High cut off Steam PAES/PVP 2.1 52.0 10 ± 2
PAES polyarylethersulfone, PVP polyvinylpyrrolidone, PA polyamide, UF ultrafiltration aeffective Stokes-Einstein radius: calculated from molecular weight cut-off
measured with polydisperse Dextrane
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Belgium), aiming at a contamination level of the dialysate
above 4 EU/ml. A sampling port was placed between the
contamination inlet port and the inlet of the dialyzer to
assess the level of contamination. A schematic figure of
the experimental set-up is shown in Fig. 1.
Samples of the dialysate were taken after 5 and
55 min. The PVP pool was sampled in duplicate before
the start (PVPstart) and at the end (PVPpost) of the ex-
periment. For the PVPpost solutions the LAL activity of
the duplicates is reported separately, but the sample was
considered positive for endotoxin if at least one con-
tained a measurable endotoxin level. All samples were
stored in pyrogen free glass tubes (Lonza, Walskersville,
MD, USA). For the endotoxin quantification, samples
were stored at 4 °C for a maximum of 24 h; for the cyto-
kine induction assay samples were stored at −20 °C until
analysis.
For decalcification and disinfection of the dialysis ma-
chine fluid path, a CleanCart C® (Gambro) cartridge was
used in combination with a heat disinfection program
after each experiment. For each experiment a new set of
tubings was used.
Endotoxin quantification
For quantification of intact LPS in the challenge solu-
tion, the dialysate and the PVP, the LAL test, a
Table 2 Overview of the experimental steps of the in vitro dialysis
Experimental Step Solution Blood side Circulation blood side Time (min) QB (ml/min) QD (ml/min) QF (ml/min) Infusion
Contaminant
Priming Blood circuit NaCl Discard 5 100 ml/min 0 0 none
Priming Dialysate circuit None – 2 0 500 0 none
Exchange fluid in Blood circuit Plasma Discard ~2a 200 0 0 0
Coating Plasma Recirculate 40 200 0 0 0
Rinsing PBS 1× Discard 18 200 0 30 0
Exchange fluid in Blood circuit PVP Discard ~2a 200 0 0 0
Dialysis PVP Recirculate 60 400 500 0 10 ml/min
atime depends on volume of circuit + membrane. For Polyflux: 1′56″; Revaclear: 1′53″; Theranova: 1′52″; Theralite: 2′07″
Fig. 1 Schematic overview of the dialysis set-up. After priming both blood and dialysate circuit and after coating the test membrane with plasma,
3 L of PVP solution, continuously mixed, was recirculated at 37 °C at the blood side at a blood flow rate QB of 400 ml/min. Samples of the PVP
were taken from the pool before and after the experiment. The dialysate was prepared by the AK200 and circulated at a flow QD of 500 ml/min.
Before entering the membrane contaminant was infused at a flow Qinf of 10 ml/min by means of a pump. Samples from the dialysate were taken
just before the membrane at 5 and 55 min. Ultrafiltration QF was set at 0 ml/min
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quantitative kinetic and chromogenic assay (Kinetic-
QCL®) (Lonza), was used. The detection limit of this
assay is 0.005 EU/ml. The test was applied according to
the manufacturer’s guidelines.
Cytokine induction assay with a THP-1 cell line
To evaluate the biological activity of potential contamin-
ation in the tested solutions, the THP-1 assay was used
as described previously [27].The human monocytic cell
line THP-1 (ATCC, LGC, Promochem, Middlesex, UK)
was maintained as a continuous culture. Cell cultures at
a density of 1 × 106 cells/ml were differentiated with cal-
citriol (10 nM; Sigma-Aldrich, St Louis, MO, USA) for
72 h. Afterwards the medium was refreshed, followed by
a 24 h rest period. The differentiated THP-1 cells were
incubated in a 1:1 dilution (with a total volume of
700 μl) with the test solutions (dialysate, PVPpre and
PVPpost) in polystyrene, pyrogen-free culture plates
(Nunc, Roskilde, Denmark) for 24 h in a humidified at-
mosphere of 5% CO2 at 37 °C. A sample of the cell cul-
ture medium was included as a negative control and 25
EU/ml LPS (E. coli 055:B5; Lonza) in PBS was included
as a positive control. After incubation, the culture sus-
pensions were collected and stored at −20 °C. After a
centrifugation step (5 min, 3000 rpm) IL-1β was quanti-
fied in the culture supernatant using a sandwich ELISA
kit (Quantikine, R&D Systems, Abingdon, UK) according
to manufacturer’s guidelines.
Logarithmic retention value
As a measure of endotoxin retention capacity the loga-
rithmic retention value (LRV) for each of the mem-
branes was calculated using the following equation:
LRV ¼ log10
Endotoxin Dialysate50þDialysate5502
Endotoxin PVPpost
Statistics
Data are expressed as mean ± SD. Measurements below
the limit of detection of the LAL-assay were replaced by
the LOD/√2 [39]. Statistical analysis was performed
using a One-way ANOVA or an unpaired T-test using
GraphPad Prism 4.0. A p-value of less than 0.05 was
considered significant.
Results
Assay compatibility of PVP
PVP dissolved in PBS (PVPPBS) at a concentration of
12.5 g/L was evaluated for its possible interference with
both the LAL-assay and the THP-1 assay. In the LAL-
assay, PBS and PVPPBS were tested per se and as a dose re-
sponse with LPS in PBS and PVPPBS. The LPS retrieved
with the LAL-assay was within the acceptable range of
50%–200% of the added concentration (data not shown)
[40]. In the THP-1 assay, PBS and PVPPBS were evaluated
per se and in combination with 45 EU/ ml LPS. THP-1
cells did not produce IL-1β in the presence of PBS and
PVPPBS, but when LPS was added the cytokine expression
was comparable to the response of LPS dissolved in PBS
as such (data not shown). Thus the combination of PVP
dissolved in PBS does neither interfere with the results of
the LAL nor with the THP-1 assay.
Permeability of dialysis membranes for bacterial filtrates
Table 3 shows the individual and the mean LAL assay
responses for the dialysate and PVP solutions per indi-
vidual experiment, categorized per membrane.
Although dialysate-endotoxin concentration varied
between 3.2 and 33.7 EU/ml in the individual experi-
ments, mainly due to the difficulty of filtrate preparation
and complexity of the experimental set-up, the mean
exposure to endotoxins through the contaminated
dialysate was above the intended minimum 4 EU/ml for
each of the different experiments and did not differ
between the different membranes. No correlation was
found between endotoxin load and permeability.
LAL activity in the PVP solution at the blood side of
the dialyzer was below the limit of detection (LOD =
0.005 EU/ml) both before (PVPpre) and after the experi-
ment (PVPpost) for 12 out of 24 tested dialyzers. Endo-
toxin levels were below LOD in all but three PVPpre
solutions. This potentially indicates contamination
occurred already before the start of the experiment in
these three experiments. Positive PVPpost reading higher
than the corresponding PVPpre reading, indicating pos-
sible contamination from endotoxin in the dialysate, was
found in 9 out of 24 experiments (low-flux: 1/6; high-
flux: 1/6; MCO 3/6; HCO: 4/6) however, there was no
apparent correlation between the individual endotoxin
challenge concentrations and the detectable readings
and in three of these cases only one of the duplicate
tests was positive.
Logarithmic retention value
Using the LAL-data as measured above, the LRV values
vary from 3.09 ± 0.50 for HCO membranes over 3.16 ± 0.29
and 3.21 ± 0.28 and for low-flux and MCO membranes
respectively to 3.29 ± 0.46 for the high flux membranes. No
statistical differences were found between the four
membrane types.
Cytokine induction assay
As shown in Table 4, 25 EU/ml LPS and the contaminated
dialysate significantly induced IL-1β expression, whereas
none of the PVP solutions used in the different experi-
ments induced IL-1β expression neither before or at the
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end of the experiments. Moreover, no significant differ-
ence in induction of IL-1β expression was found between
the PVP solutions treated with the different membranes.
Discussion
In the present study a new, clinically more representa-
tive model to test permeability of dialyzers for endo-
toxins is demonstrated. It is to our knowledge the first
time that permeability of membranes was tested using a
relevant, realistic set-up mimicking real life settings and
conditions. Using this set-up, four dialysis membranes of
comparable composition but with different pore size
were tested for their permeability for endotoxins by ex-
posing them during a 1 h in vitro dialysis session to di-
alysate contaminated with filtrates of two water-borne
bacteria, P. aeruginosa and P. saccharophila, at an endo-
toxin challenge at least four times the upper limit of
endotoxin load (2 EU/ml) when using standard dialysis
fluid [26]. For the tested membranes, there was a non-
significant difference in number of the PVP solutions
which contained a detectable amount of endotoxin after
repetitive circulation through the dialyzer, be it close to
the detection limit in the majority of cases. It was
chosen to give the individual data from all experiments
as this is the most exact way to present the data and to
give the reader full visibility of the data. The PVP solu-
tions in many cases had a measured LAL activity below
the LOD and the individual numbers give a better im-
pression of the limited degree of contamination in case
values were above LOD in the blood compartment. It
might be speculated that increasing the number of
experimental repeats could lead to statistical significance
in the differences between the membranes, however this
will not change the clinical relevance of the low degree
of contamination. Interestingly, there was no dose-
response correlation between the level of contamination
within the tested range of dialysate endotoxin concentra-
tion and the detectable concentration of endotoxin in
the PVPpost solutions, neither across the whole data set
(all tested dialyzers) nor in any of the individual data sets
(the four membranes tested). None of the PVP solutions
induced measurable IL-1β expression in the THP-1
assay, and there was no difference in the logarithmic re-
tention values as based on the measured LAL-levels, and
Table 3 Endotoxin levels in the dialysate and the PVP solution
per membrane measured by the LAL-assay (n = 6 for each
membrane). LOD was 0.005 EU/ml
Membrane Dialysate
(EU/ml)
PVPpre
(EU/ml)
PVPpost (EU/ml) Statistics
PVPpre vs
PVPpost
Duplicate
1
Duplicate
2
Low-flux 3.5 < LOD < LOD < LOD
3.9 < LOD < LOD < LOD
5.5 < LOD < LOD < LOD
9.4 < LOD < LOD < LOD
10.3 < LOD 0.011 < LOD
19.1 < LOD < LOD < LOD n.s.
Mean ± SD 8.6 ± 5.8
High-flux 3.6 < LOD < LOD < LOD
4.1 0.008 0.007 0.008
5.9 < LOD 0.005 < LOD
6.1 < LOD < LOD < LOD
20.0 0.007 < LOD < LOD
33.7 < LOD < LOD < LOD n.s.
Mean ± SD 12.2 ± 12.2
Medium cut-off 6.0 < LOD 0.023 0.005
6.3 < LOD < LOD < LOD
6.8 < LOD < LOD < LOD
8.0 < LOD 0.006 0.005
10.6 < LOD 0.005 0.005
11.8 < LOD < LOD < LOD n.s.
Mean ± SD 8.3 ± 2.4
High cut-off 3.2 < LOD 0.019 0.013
4.1 < LOD 0.005 0.005
5.4 < LOD 0.005 0.005
5.8 < LOD 0.005 < LOD
12.1 < LOD < LOD < LOD
22.5 0.006 0.005 0.005 n.s.
Mean ± SD 8.9 ± 7.4
Data with measurable endotoxin levels were written in italic and when they
were higher than the PVPpre value they were additionally put in bold
and underlined
Table 4 Overview of IL-1β expression in pg/ml in the THP-1 cytokine induction assay by the dialysate and PVP solutions
Medium LPS 25EU/ml Dialysate PVPpre PVPpost Statistics
°
Low-flux 11.44 ± 4.05 53.78 ± 21.11* 51.69 ± 57.07 10.87 ± 4.02 10.53 ± 4.22 n.s.
High-flux 12.86 ± 3.43 62.03 ± 22.91* 88.4 ± 122.13 11.87 ± 3.09 11.09 ± 2.82 n.s.
Medium cut-off 11.93 ± 3.54 54.71 ± 20.85* 40.99 ± 60.49 12.11 ± 3.55 11.13 ± 2.87 n.s.
High cut-off 12.25 ± 3.69 59.97 ± 17.22* 22.78 ± 21.88 11.55 ± 3.69 11.30 ± 3.18 n.s.
* p < 0.05 vs Medium; °PVPpre vs. PVPpost
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for none of the devices the LAL activity changed signifi-
cantly PVPpost vs. PVPpre.
Over the last years, membranes with larger pore sizes,
such as MCO and HCO, have been introduced in an
attempt to reduce inflammation and cardiovascular tox-
icity in patients with ESKD by an enhanced clearance of
middle molecular weight substances during dialysis. Sev-
eral trials have meanwhile provided evidence suggesting
that larger pore membranes indeed enhance clearance of
different middle molecules, and can reduce inflamma-
tion and calcification. A study in hemodialysis patients
treated with HCO vs. high-flux membranes demon-
strated by exposing THP-1 monocytes their serum or to
the dialysate that HCO membranes eliminate a spectrum
of pro-inflammatory mediators from serum into the
dialysate [41]. In patients with signs of chronic mild
inflammation (C-reactive protein (CRP) > 5 mg/l), use of
HCO in series with a low-flux dialyzer resulted in a
dampening of systemic inflammation markers such as
soluble TNF receptor 1 (sTNFR1), associated with (car-
diovascular) outcomes in observational CKD cohorts
[42], but not of expression density of the P-selectin
receptor CD162 on monocytes in pre-dialysis blood
samples [15]. In an unblinded randomized cross over
study comparing hemodialysis of equal duration using a
high-flux vs. an MCO membrane during 4 weeks each,
pre-dialysis TNF-α and IL-6 mRNA expression levels in
white blood cells were reduced when using MCO com-
pared to conventional high flux, but no effect was
observed on CRP levels [23]. In addition, TNFR1 and
kappa and lambda free light chains serum levels were
reduced more effectively by MCO. Unfortunately, these
studies did not assess actual removal of these substances,
so it remains unclear whether the effects were due to
reduced production or to enhanced clearance of the
retention products. Also, it is remarkable that the effect
of using larger pores only influenced levels of some and
not all cytokines, despite them having the same range of
molecular weight. This might point to differences in dis-
tribution volume, or in generation rate.
These studies, while promising, still refer to surrogate
markers assessed. So far, no study of the impact of MCO
or HCO membranes on patient relevant (hard) end-
points, such as mortality, cardiovascular events or even
quality of life has been performed. The clinical benefits
of the use of MCO and HCO, while promising, thus still
need further underpinning.
Upregulation of production of cytokines by the use of
the larger pore size membranes might be of concern
when their usage would result in pro-inflammatory fac-
tors by transmigration of contaminants from the dialys-
ate side. So far, all of the above mentioned studies have
been performed in a setting where ultrapure dialysate
was used. If the use of larger pore membranes would
result in a substantial transmembrane transport of bac-
terial degradation products in settings with poor water
quality, the positive effects of this type of membranes on
inflammation could potentially be completely annihi-
lated by the added inflammatory burden induced by
these translocated contaminants. A case-study by Gong
et al. reported a risk for endotoxemia when using an
HCO membrane in combination with conventional dia-
lysis fluid (0.112–0.141 EU/ml) [43]. However these re-
sults rely on a single measurement and as reviewed by
Wong et al. caution should be taken when measuring
endotoxin levels in blood using the LAL assay as its sen-
sitivity and specificity for biological samples is poor [44].
The present experiments demonstrate that, when using
a 4-fold overload of endotoxin, the use of larger pore
membranes, MCO and HCO, is likely safe from that re-
gard. Indeed, in none of the experiments, biological acti-
vation of the inflammatory system was observed as
measured by a IL-1β production by the THP1-assay,
sensitive for several bacterial components such as intact
LPS, LPS fragments, peptidoglycan and short bacterial
DNA fragments [27]. In the majority of experiments, no
measurable transmembrane migration of endotoxin took
place. The highest measured level of endotoxin in a du-
plicate sample from the ‘patient side’ was 0.023 EU/ml.
This corresponds to a total amount of about 70 EU
transferred during the 1 h dialysis session, and thus a
transfer rate of about 1 EU/kg/h (mean patient of 70 kg),
which is still well below the pyrogenicity limit of 5 EU/
h/kg body weight (the minimum dose that induces fever)
for injectable medications and devices [26].
Of note, our experimental set-up is a worst case sce-
nario in which endotoxin exposure is 4-fold greater than
permitted in standard (not ultrapure!) dialysate, spread
over a 4 h dialysis session. It is of note that most modern
dialysis monitors have an additional ultrafilter between
permeate and dialysate, providing an extra safeguard for
contamination that was bypassed in our set-up infusing
the contaminant at the dialyzer inlet. Our results dem-
onstrate that in facilities where water quality is within
ISO standards of regular dialysate quality, the risk for
cross-contamination of the blood side by endotoxins
from the dialysate side when using membranes with lar-
ger pores is limited. In this type of setting, and by exten-
sion of course also in the setting of ultrapure dialysate,
use of large pore membranes can potentially result in a
dampening of chronic micro-inflammation. Larger long-
term clinical trials with patient relevant outcomes are
warranted to evaluate this hypothesis.
Special emphasis was made in the present study to de-
velop an experimental model mimicking the clinical
reality as close as possible. In the setting of the investiga-
tion of transmembrane migration of endotoxins from
the dialysate to the blood side of the dialyzer, it is also
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important to keep in mind that this migration can not
only take place by diffusion, but also by backfiltration.
Backfiltration of contaminants can be influenced by
properties of the membrane, such as pore size, surface
area, and geometrical configuration of the fibers; by
ultrafiltration rates, and thus by the hydraulic set-up of
the dialysate circuit; by the viscosity of the solution cir-
culating at the blood side of the membrane [45, 46].
Therefore, it was opted to use full size dialyzers rather
than down-sized models, and these were assembled on a
dialysis monitor as used in daily clinical practice, rather
than using separate pumps to circulate the dialysate and
the surrogate blood solution. Furthermore, to exclude
confounding by differences in polymers, dialyzers of
comparable membrane composition from a single manu-
facturer were chosen to focus on the investigation of
variation in pore size. Therefore, the results of our inves-
tigation can likely not be generalized to membranes of
different compositions or structure. The dialysate and
blood flows were comparable to the ones applied in the
clinic and in the same context, viscosity of the fluid cir-
culating in the blood compartment was comparable to
that of blood, mimicking clinical pressure distributions
in the dialyzer and with it, realistic filtration profiles. To
create a worst-case scenario ultrafiltration was set at
0 ml/min, resulting in a maximal backfiltration. It was
opted not to use whole blood for the experiments since
this is indeed cumbersome and expensive. In addition,
concerns have been raised in the past that the use of
whole blood in this type of experimental set up might
abrogate activity of endotoxins as several components of
whole blood have the capacity to neutralize endotoxins.
The use of whole blood would thus potentially result in
a false negative results when endotoxin transfer is being
investigated [47].
Further, it was opted to apply a protein coating to the
tested membranes by circulating a human plasma solution
before the beginning of the experiments in order to mimic
the properties of the synthetic membranes during dialysis,
[37]. The differences in membrane properties after contact
with blood can be attributed to the adhesion of proteins
to the membrane surface, and is related to the membrane
material [38, 48, 49]. A protein layer, also referred to as
secondary layer, is created on top of the membrane due to
the adhesion of proteins to the membrane surface, and
acts also as a barrier for the transport of substances. It is
known to be a process that is not instantaneous [49], but
that occurs during the first hour of treatment [48]. This
phenomenon cannot be described with the PVP model so-
lution since the PVP molecules are unlikely to adsorb to
the membrane surface. The coating is important with re-
spect to biocompatibility in vivo [50], but it also decreases
transport through the membrane and in this way also
backfiltration of contaminants [37].
Finally, it is also important to use a relevant inoculum
to create the endotoxin load. Sterile filtrates of P. aerugi-
nosa and P. saccharophila were used as source of endo-
toxins, as they are relevant water-borne bacteria
retrieved in dialysis circuits [36]. Preparations of bacteria
can contain a wide range of contaminants and endo-
toxins with different molecular weight and thus different
properties with regards to transmembrane transport.
Not all of these bacterial products might test positive in
the LAL test, but they do have a cytokine inducing cap-
acity as assessed by the production of IL-1β by the THP-
1 cell line in the bio-assay. Considering all these issues,
the model presented here is very close to the clinical
reality, adding more weight to the results and observa-
tions shown.
Remarkably, none of the PVP solutions induced a bio-
logical response as assessed by activity of human THP-1
monocytes higher than that of the background culture
medium, despite the fact that in some of the PVP samples
endotoxin was detectable. As demonstrated by Glorieux et
al., the THP-1 assay only induces a significant increase in
IL-1β expression in the presence of 0.1 ng/mL LPS
(1.25EU/ml), comparable to the response of monocytes in
healthy blood [27]. So based on the endotoxin levels quan-
tified by the LAL-test, no induction of IL-1beta expression
is to be expected. In contrast to the LAL-test, the THP1-
assay reacts to more than endotoxin alone, suggesting that
levels of other possible bacterial degradation products
were also in the lower range.
Conclusions
A realistic and feasible model to assess dialysis mem-
brane translocation of bacterial degradation products
present in the dialysate was developed and applied to
test the retention capacity of 4 different membranes with
similar chemical composition but different pore sizes.
Although more blood side PVP solutions had a detect-
able amount of endotoxin using a highly sensitive LAL
assay in the more open vs traditional membranes the
permeability for endotoxins of the 4 tested dialysis mem-
branes was not significantly different. Moreover, none of
these PVPpost solutions induced IL-1β expression in the
THP-1 based bio-assay that is sensitive also to other
bacterial byproducts.
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